The three partners in Roche ’n’ Jazz
About the Museum Tinguely
The Museum Tinguely, which was founded in 1996 and is dedicated to the work of the Swiss metal sculptor Jean Tinguely, is a cultural commitment by Roche. In addition to its permanent exhibition of the machine sculptures and graphic works of Jean Tinguely, who died in 1991, the museum also hosts special exhibitions that give an insight into the art and artists who influenced and were associated with Tinguely, kinetic art and 20th and 21st-century art. Current and past exhibitions have been dedicated to such friends and partners of Tinguely as Niki de Saint Phalle, Yves Klein or Eva Aeppli; to role models such as Marcel Duchamp, Kurt Schwitters or Max Ernst; and to more recent trends such as contemporary kinetic art. Exhibitions always focus on new areas of art. Further information on the Museum Tinguely can be found on its website www.tinguely.ch.
About bird's eye jazz club
Basel's bird's eye jazz club enjoys an excellent reputation among jazz musicians the world over, ranking as one of the most highly in-demand and renowned small venues in Europe. The quality of the acts that perform at bird's eye is correspondingly high. Its line-up of international acts and top Swiss, local or up-and-coming talent offers audiences plenty of variety and encourages international exchanges among musicians. The pleasant and welcoming atmosphere of the city-centre club and the close proximity between audience and performers is highly appreciated by all. In addition to its programme of modern contemporary classical jazz concerts, the club encourages encounters across stylistic boundaries – e.g. with classical, hip-hop or Latin – by taking part in innovative musical projects and networking with other promoters. bird's eye is now an essential and established part of the cultural scene in and around Basel. Further information on bird's eye can found on its website www.birdseye.ch.
(bird's eye jazz club facebook)
About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80’000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
